Biotechnology company Cartography Biosciences Inc announced on Tuesday that it has entered a multi-year collaboration with biopharmaceutical company Pfizer Inc (NYSE:PFE) to discover tumour-selective antigens.
Under the agreement, Cartography will apply its ATLAS and SUMMIT platforms to identify and validate antigens in an undisclosed oncology indication. Pfizer may opt-in on multiple antigens and will lead all research, development, and commercialisation for selected programmes.
Cartography's lead programme, CBI-1214, will remain wholly owned and independently advanced.
The ATLAS and SUMMIT platforms analyse antigen expression across healthy and tumour cell states to identify targets with optimal tumour selectivity.
Cartography is eligible to receive up to USD65m in upfront, near-term milestone, and option exercise payments. The collaboration carries a potential total value exceeding USD850m, including future development, regulatory, commercial milestones, as well as tiered royalties on net sales.
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
Organon signs commercialisation agreement for Nilemdo across six European markets
Antin to acquire clinical trial equipment provider Emsere
Arbele's ARB1002 receives US FDA Orphan Drug Designation
Eli Lilly agrees to acquire Ventyx Biosciences
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
GSK wins European Commission approval for Shingrix prefilled syringe
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Day One completes Mersana acquisition to add rare cancer antibody drug conjugate
Cartography Biosciences partners with Pfizer to discover tumour-selective antigens